Sai Parenterals Limited plans Noumed manufacturing shift

Sai Parenterals Limited plans to shift Noumed’s contracted Australian and New Zealand supply book towards internal manufacturing from FY27. The business has 15 exclusive supply agreements covering 491 stock-keeping units (SKUs), while products sourced largely from third-party manufacturers currently yield an approximately 10% distribution margin. Sai expects Adelaide commissioning and expanded Indian capacity to change that supply model.

What did Sai acquire through Noumed?

Sai acquired a platform with 15 exclusive long-term supply agreements covering 491 SKUs for Australian and New Zealand pharmacy chains. Typical agreements run for more than five years and include annual forecasts for individual products. The contracted Australian over-the-counter, or OTC, book is stated at AUD 232 million, or about Rs 1,506 crore.

Noumed supplies private-label OTC and prescription products, but pharmacy chains own the consumer brand while Noumed holds the product registration. That registration-holder role underpins the supply agreements. The platform also earns separate service and fee income from third-party logistics, regulatory support and pharmacovigilance, which the presentation describes as annuity-like because it is independent of product margin.

The customer base includes Wesfarmers Health, supplied through Priceline private label and Pharmacy Health, and EBOS Group, supplied through TerryWhite Chemmart and Pharmacy Choice. Sai says the Wesfarmers Health, EBOS and Sandoz Warehouse networks together cover 2,900 of Australia’s 5,500 pharmacies. In New Zealand, contracts are won through Pharmac tenders supported by exclusive intellectual-property rights on several registered products.

How will Sai move Noumed supply in-house?

Sai plans to move a material share of Noumed’s third-party sourcing to its own facilities from FY27, converting distribution margin into manufacturing margin on the same contracted revenue. Noumed currently sources product largely from third-party contract manufacturers, producing an approximately 10% distribution margin. The presentation does not specify the share of products to be transferred, the expected manufacturing margin or the resulting profit contribution.

The sourcing change is planned alongside the use of Sai’s packaging, raw-material and active pharmaceutical ingredient, or API, procurement. Management says this upstream integration can lower input costs. Noumed already manages batch release, warehousing, distribution, regulatory work and pharmacovigilance, meaning that the group controls the registration and customer relationship before manufacturing is brought into the model.

Service-level agreements and minimum-supply obligations require Noumed to hold nine to 10 months of inventory. Sai attributes part of this position to a 60-day shipping lead time. The presentation says Adelaide commissioning is expected to remove that shipping delay, but it does not quantify the resulting inventory reduction or working-capital effect.

What does the Adelaide facility add to Sai’s plan?

The Adelaide facility is intended to make tablets, liquid oral products, nasal sprays, creams and ointments, providing local production for the Noumed supply platform. Total planned capital expenditure is AUD 53 million, stated as Rs 311 crore, and AUD 46 million had been invested at the time of the presentation. The balance is to be funded through debt and accruals, while the project has received an AUD 20 million Australian federal government grant.

The grant conditions require 150 jobs by 2027 and sovereign manufacturing capability. Sai anticipates a Therapeutic Goods Administration, or TGA, licensing inspection by 31 March 2027. A separate slide places Phase 1 manufacturing from Q4FY27, so the presentation identifies both a regulatory milestone and a production-stage target without providing a final commissioning date.

Adelaide is designed to complement Sai’s Indian capacity rather than replace it. The presentation lists regulatory-approved facilities at Bhongir and Bollaram in Telangana and Ongole in Andhra Pradesh. It also says Units I and II at Jeedimetla are to be replaced by Saicrit’s injectable facility at Gummadidala, while Indian capacity expansion supports the planned transfer of Noumed supply.

How do Noumed’s dossiers support the strategy?

Sai acquired more than 451 TGA dossiers with Noumed, giving it registrations that support pharmacy-chain supply agreements and additional market filings. The dossier library was assembled over five years through in-licensing, portfolio purchases and organic development. Sai estimates that organic construction of a library at that scale would have taken 10 to 15 years.

The presentation says an Australian dossier can shorten the time to launch in a new export market to six to nine months, compared with 18 to 24 months without the library. TGA-approved dossiers are being leveraged for filings in Latin America, South-East Asia, the Middle East and Africa, where Sai says distribution relationships are already in place. The material does not identify approval outcomes in individual countries.

Sai reported 88 dossier approvals across regulated and emerging markets in FY26, plus five added by Noumed in Australia in Q4FY26. It also listed 76 dossiers under development for FY28. The registration library therefore supports both the existing 491-SKU supply book and the stated plan to use Australian approvals in other export markets.

Conclusion

Sai’s Noumed strategy combines 15 contracted supply agreements, 491 SKUs and more than 451 TGA dossiers with a plan to internalise product manufacturing. The immediate business model retains an approximately 10% distribution margin on largely third-party-sourced products, while separate logistics, regulatory and pharmacovigilance services generate fee income. The proposed change is to manufacture more of the existing contracted supply internally while retaining Noumed’s registration-holder role.

The next disclosed milestones are the anticipated TGA licensing inspection by 31 March 2027, Phase 1 Adelaide manufacturing from Q4FY27 and the grant requirement to create 150 jobs by 2027. The presentation also identifies a material in-house sourcing transfer and a reduction in the current nine-to-10-month inventory position as intended outcomes, but does not quantify either target.